Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 1, 2025
Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook
GlobeNewswire
·
May 1, 2025
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to …
As Skin Cancer Rates Climb, Canadian Dermatologists Champion Sun Safety Nationwide this May
GlobeNewswire
·
May 1, 2025
OTTAWA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- As the warmth of the sun returns and Canadians begin to spend more time outdoors, the Canadian Dermatology Association (CDA) launches its annual Sun Awareness Month campaign. This year’s campaign, through …
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
GlobeNewswire
·
May 1, 2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation- …
AB Science will publish its 2024 annual financial report on May 9, 2025
GlobeNewswire
·
May 1, 2025
PRESS RELEASE THE COMPANY WILL PUBLISH ITS 2024 ANNUAL FINANCIAL REPORT ON 9 MAY 2025 Paris, May 1st 2025, 10am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, …
AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025
GlobeNewswire
·
May 1, 2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION LE 9 MAI 2025 DE SON RAPPORT FINANCIER ANNUEL 2024 Paris, 1er mai 2025, 10h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui le décalage de la publication de son rapport financier …
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
GlobeNewswire
·
May 1, 2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs …
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
GlobeNewswire
·
May 1, 2025
Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio, a biopharmaceutical company pioneering the development of …
Roquette Completes the Acquisition of IFF Pharma Solutions
GlobeNewswire
·
May 1, 2025
Roquette Completes the Acquisition of IFF Pharma Solutions Lille, May 1, 2025 – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the successful completion of its acquisition …
Roquette finalise l’acquisition d’IFF Pharma Solutions
GlobeNewswire
·
May 1, 2025
Roquette finalise l’acquisition d’IFF Pharma Solutions Lille, le 1 mai 2025 – Roquette, un leader mondial des ingrédients d'origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé et de la nutrition, annonce la finalisation de …
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
GlobeNewswire
·
May 1, 2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext …
Used and new teen vehicles for every budget
GlobeNewswire
·
May 1, 2025
ARLINGTON, Va., and YONKERS, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Families with newly licensed teens have a wide range of options this year when it comes to safe vehicles for their novice driver. An updated list of suggested vehicles for teens from the …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
GlobeNewswire
·
May 1, 2025
TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today announced that the U.S. Food and Drug Administration (FDA） has cleared an investigational new drug （IND） application for OBI-902, …
浩鼎ADC OBI-902临床试验获美国FDA核准 将启动Trop-2靶向ADC 1/2期临床研究
GlobeNewswire
·
May 1, 2025
台湾, May 01, 2025 (GLOBE NEWSWIRE) -- 致力于癌症创新疗法研发的台湾浩鼎生技（4174.TWO）今（5/1）日（美国时间4/30）宣布，旗下新药OBI-902已获美国食品药物管理局（FDA）核准临床试验申请（IND），将展开一期/二期临床试验。这项试验预计招募晚期实体肿瘤患者。浩鼎视此次通过IND，为开发进程的重要里程碑，代表此一新世代Trop-2 ADC，将为未被满足医疗需求的患者提供新的治疗希望。 浩鼎执行长王慧君博士表示，即将开展的OBI-902-001 …
浩鼎ADC OBI-902臨床試驗獲美國FDA核准 將啟動Trop-2靶向ADC 1/2期臨床研究
GlobeNewswire
·
May 1, 2025
台灣, May 01, 2025 (GLOBE NEWSWIRE) -- 致力於癌症創新療法研發的台灣浩鼎生技 （4174.TWO） 今（5/1）日（美國時間4/30） 宣布，旗下新藥OBI-902已獲美國食品藥物管理局（FDA）核准臨床試驗申請（IND），將展開一期/二期臨床試驗。這項試驗預計招募晚期實體腫瘤患者。浩鼎視此次通過IND，為開發進程的重要里程碑，代表此一新世代Trop-2 ADC，將為未被滿足醫療需求的患者提供新的治療希望。 浩鼎執行長王慧君博士表示，即將開展的OBI-902-001 …